tirzepatide cardiovascular outcome trial An Observational Study of Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists SURPASS-CVOT Published: Large Trial Confirms

It is not considered an addictive substance but users can develop a dependence and experience withdrawal when they stop taking the medication

I love how it suppresses my appetite

This post was written by our team of health writers for informational purposes only and does not constitute medical advice

Blood-sugar control and glycemic outcomes may still improve or continue improving (especially if you had diabetes or impaired glucose management) retatrutides mechanism supports glucose control in addition to weight-loss

Weight loss results average around 8%, roughly 60% less than what Tirzepatide achieves

Switch if: you experience severe acid reflux or GERD symptoms specifically on injection nights despite maintaining a 2 to 3 hour buffer before lying down